{
  "id": "biontech-s-mrna-pivot-drives-fresh-investor-optimism",
  "title": "BioNTech’s mRNA pivot drives fresh investor optimism",
  "summary": "As shares rebound, investors are weighing whether the biotech’s immuno-oncology pipeline could define its next chapter. If you’ve been watching BioNTech, the German biotech widely known for developing the first mRNA-based COVID-19 vaccine (Comirnaty), the recent share price jump might feel like déjà vu: $118 per share, up 22% year-to-date and nearly 25% over the […] The post BioNTech’s mRNA pivot drives fresh investor optimism appeared first on Longevity.Technology.",
  "url": "https://longevity.technology/news/biontechs-mrna-pivot-drives-fresh-investor-optimism/",
  "source": "Longevity.Technology",
  "author": "Kyle Umipig",
  "category": "news",
  "publishedAt": "2026-01-29T18:01:13.000Z",
  "fetchedAt": "2026-02-04T10:49:05.819Z",
  "relevanceScore": 0.2,
  "matchedKeywords": [
    "longevity"
  ],
  "relatedProducts": [],
  "type": "web",
  "savedAt": "2026-02-04T10:49:05.892Z"
}